Activity

Filter

Cancel
Date Panel Item Activity
8 actions
Speech apraxia v1.32 SMARCA2 Zornitza Stark Marked gene: SMARCA2 as ready
Speech apraxia v1.32 SMARCA2 Zornitza Stark Gene: smarca2 has been classified as Green List (High Evidence).
Speech apraxia v1.32 SMARCA2 Zornitza Stark Classified gene: SMARCA2 as Green List (high evidence)
Speech apraxia v1.32 SMARCA2 Zornitza Stark Gene: smarca2 has been classified as Green List (High Evidence).
Speech apraxia v1.31 SMARCA2 Hali Van Niel gene: SMARCA2 was added
gene: SMARCA2 was added to Speech apraxia. Sources: Expert List,Literature
Mode of inheritance for gene: SMARCA2 was set to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
Publications for gene: SMARCA2 were set to 41530369; 39931922; 32694869
Phenotypes for gene: SMARCA2 were set to Nicolaides-Baraitser syndrome (MIM#601358); Blepharophimosis-impaired intellectual development syndrome (MIM#619293)
Review for gene: SMARCA2 was set to GREEN
Added comment: Two reported individual with CAS and de novo missense variants (c.2870 A > G; p.(Gln957Arg); c.3484 C > T; p.(Arg1162Cys)) (Van Niel et al., 2026; PMID: 41530369), Validated diagnostic findings from VCGS clinical NATA pipeline

Mitchel et al. (2025; PMID: 39931922) report one individual with CAS and SMARCA2 variant (Supp Table 6).

Phenotype dependent on variant position along gene (PMID: 32694869). Both phenotypes implicated with CAS.
Sources: Expert List, Literature
Speech apraxia v1.23 Zornitza Stark removed gene:SMARCA2 from the panel
Speech apraxia v1.6 SMARCA2 Thomas Scerri Deleted their review
Speech apraxia v1.6 SMARCA2 Thomas Scerri gene: SMARCA2 was added
gene: SMARCA2 was added to Speech apraxia. Sources: Expert list,Expert Review
Mode of inheritance for gene: SMARCA2 was set to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
Phenotypes for gene: SMARCA2 were set to Blepharophimosis-impaired intellectual development syndrome, MIM# 619293; Nicolaides-Baraitser syndrome, MIM# 601358
Review for gene: SMARCA2 was set to RED
Added comment: Two in-house (as yet unpublished) CAS probands with pathogenic variants.
Sources: Expert list, Expert Review